Open-label Placebo

Preclinical

RRhode Island Hospital

Open-label Placebo is one of 8 therapeutic programs targeting Cancers. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

CancersRecruiting

CancersPreclinical

Recruiting

Competition

Competitive Landscape

10 competitors in Cancers

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 2

2 2

Tafinlar

Novartis

Phase 2

1 3

Mekinist

Novartis

Phase 2

1 4

Gleevec

Novartis

Phase 2

1 5

Jemperli

GGlaxo Dba Glaxosmithkline

Phase 2

1 6

Hyperpolarized 13c Pyruvate

UUniversity of Maryland, Baltimore

Phase 2

1 7

Upifitamab Rilsodotin

MMersana Therapeutics

Phase 2

3 8

Open-label Placebo

RRhode Island Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2029

PreclinicalRecruiting

Cancers

NCT06085716

Clinical

Trials by Indication[1]

Cancers1 trial

Combination Therapy for Cancer Related Fatigue in Patients With Metastatic Cancers

Recruiting·MM.D. Anderson Cancer Center·Preclinical·NCT06085716·240 enrolled

Chronic Low Back Pain1 trial

Optimizing Open Placebos for Chronic Pain Patients

Completed·RRhode Island Hospital·Preclinical·NCT06931158·327 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Open-label Placebo. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Open-label Placebo. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Rhode Island Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: RRhode Island Hospital

Open-label Placebo

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2029

Trials by Indication[1]

Cancers1 trial

Chronic Low Back Pain1 trial

References

Drug Info

Quick Facts

Related News